Cargando…

Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab

BACKGROUND: Immune checkpoint inhibition has dramatically transformed the treatment of malignant melanoma. With increasing use, their unique spectrum of immune-mediated toxicity has become apparent. CASE PRESENTATION: We describe a case of sequential immune-related adverse events (irAEs) in a patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, N., Jacob, J., Househ, Z., Shiner, E., Baird, L., Soudy, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6740018/ https://www.ncbi.nlm.nih.gov/pubmed/31511075 http://dx.doi.org/10.1186/s40425-019-0727-5

Ejemplares similares

Pembrolizumab‐caused polyradiculoneuropathy as an immune‐related adverse event
por: Kurashige, Takashi, et al.
Publicado: (2021)

Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab
por: Lima, Gian, et al.
Publicado: (2019)

Violence Unchecked by Social Distancing
por: Cannon, Jeremy W., et al.
Publicado: (2020)

IgA Nephropathy that Developed as an Immune-related Adverse Event of Pembrolizumab Complicated with Interstitial Nephritis
por: Mitarai, Yuki, et al.
Publicado: (2021)

Pembrolizumab-related Immune Thrombocytopenia in a Patient with Lung Adenocarcinoma Treated by Radiotherapy: Potential Immune-related Adverse Event Elicited by Radiation Therapy
por: Tamanoi, Daisuke, et al.
Publicado: (2021)

Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus
por: Jono, Misato, et al.
Publicado: (2019)

Reputation‐Sourced Authority and the Prospect of Unchecked Bureaucratic Power
por: Bertelli, Anthony M., et al.
Publicado: (2020)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
por: Grimaldi, Antonio Maria, et al.
Publicado: (2015)

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
por: Eun, Yeonghee, et al.
Publicado: (2019)

Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus
por: Takemura, Masao, et al.
Publicado: (2021)

Pancreatitis as immune‐related adverse event during pembrolizumab therapy for multiple lung metastases from renal pelvic cancer
por: Kokura, Kazuki, et al.
Publicado: (2023)

Pembrolizumab-Induced Lichen Planus: A Rare Immune-Related Adverse Side Effect
por: Bansal, Aditi, et al.
Publicado: (2023)

Unchecked nick ligation can promote localized genome re-replication
por: Johansson, Erik, et al.
Publicado: (2021)

Complete response in a patient with lung cancer suffering from three pembrolizumab‐induced immune‐related adverse events including retinal vasculitis
por: Mimura, Chihiro, et al.
Publicado: (2021)

A Case of Nonsmall-Cell Lung Cancer with Anaphylaxis after 41 Courses of Pembrolizumab along with Adrenal Insufficiency as an Immune-Related Adverse Event
por: Nakamura, Tomoaki, et al.
Publicado: (2022)

Vasospastic Angina: An Immune-related Adverse Event
por: Kumamoto, Taku, et al.
Publicado: (2021)

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
por: Noguchi, Susumu, et al.
Publicado: (2020)

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
por: Möhn, Nora, et al.
Publicado: (2019)

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
por: Schoenfeld, A.J., et al.
Publicado: (2019)

A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report
por: Hamada, Kazuyuki, et al.
Publicado: (2022)

Non‐bacterial cystitis with increased expression of programmed death‐ligand 1 in the urothelium: An unusual immune‐related adverse event during treatment with pembrolizumab for lung adenocarcinoma
por: Ueki, Yohei, et al.
Publicado: (2020)

THU478 Unchecked Kinase Activation Underlies Pituitary Adenomas Causing Cushing’s Disease
por: Asuzu, David, et al.
Publicado: (2023)

Cushing's syndrome in children: An unchecked consequence of steroid use by quacks in rural areas of Pakistan
por: Abidi, Syed M Aqeel
Publicado: (2023)

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
por: Moseley, Kendall F., et al.
Publicado: (2018)

Metastatic Merkel Cell Carcinoma Masquerading as Multiple Immune-Related Adverse Events
por: Saqlain, Farees, et al.
Publicado: (2020)

Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events
por: Makunts, Tigran, et al.
Publicado: (2022)

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
por: de Filette, Jeroen, et al.
Publicado: (2016)

Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked
por: Niravath, Polly, et al.
Publicado: (2015)

Immune-Related Adverse Events: Pneumonitis
por: Zhong, Linda, et al.
Publicado: (2020)

Post cardiac surgery junctional ectopic tachycardia: A ‘Hit and Run’ tachyarrhythmia as yet unchecked
por: Tharakan, Jaganmohan A, et al.
Publicado: (2014)

Intrinsic Toxicity of Unchecked Heterochromatin Spread Is Suppressed by Redundant Chromatin Boundary Functions in Schizosacchromyces pombe
por: Garcia, Jennifer F., et al.
Publicado: (2015)

Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
por: Furubayashi, Nobuki, et al.
Publicado: (2022)

Pembrolizumab-Induced Hypophysitis With Isolated Adrenocorticotropic Hormone (ACTH) Deficiency: A Rare Immune-Mediated Adverse Event
por: Doodnauth, Andrew V, et al.
Publicado: (2021)

Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event
por: Inui, Genki, et al.
Publicado: (2022)

Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer
por: Marhold, Maximilian, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Pembrolizumab: Immune-mediated pancreatitis: case report
Publicado: (2022)

Metachronous immune-related adverse events involving type 1 diabetes and isolated adrenocorticotropic hormone deficiency associated with pembrolizumab monotherapy for metastatic head and neck cancer: a case report
por: Iijima, Hiroaki, et al.
Publicado: (2023)

SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color
por: Pierre, A.B., et al.
Publicado: (2023)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kiomqufahpq1iad3q3l2vlke9s